Italiano Farmacia on line: comprare cialis senza ricetta, acquistare viagra internet.

% , "

CURRICULUM VITAE
John E. Levine, MD

EDUCATION

Aug 1981-May 1985
BA, University of Virginia, Biochemistry, Charlottesville, VA MD, Eastern Virginia Medical School, Norfolk, VA MS, University of Michigan, Clinical Research Design and Statistical Analysis, Ann Arbor, MI POSTDOCTORAL TRAINING

July 1989-June 1990
Intern in Pediatrics, Children’s Hospital of Los Angeles, Los Angeles, CA Resident in Pediatrics, Children's Hospital of Los Angeles, Los Angeles, CA Fellow in Pediatric Hematology-Oncology, Memorial Sloan-Kettering Cancer and New York Hospital, Cornell University Medical Center, New York, NY Junior Attending in Pediatric Bone Marrow Transplantation, Memorial Sloan Kettering Cancer Center, New York, NY
ACADEMIC APPOINTMENTS

Sep 1995-Aug 2002
Assistant Professor of Pediatrics, Clinical Track, University of Michigan Associate Professor of Pediatrics, Clinical Track, University of Michigan Associate Professor of Internal Medicine, Clinical Track, University of Michigan Professor of Pediatrics and Internal Medicine, Clinical Track, University of Michigan
ACADEMIC ADMINISTRATIVE APPOINTMENTS

Jan 1996-Dec 1997
Associate Medical Director, Comprehensive Sickle Cell Program, University of Michigan Medical Director, Comprehensive Sickle Cell Program, University of Michigan Clinical Director, Pediatric Blood and Marrow Transplantation, University of Michigan Medical Director, Pediatric Hematology/Oncology/BMT, Ambulatory Chair, Data and Safety Monitoring Board, University of Michigan Cancer Center
HONORS
1993
American Society of Hematology Travel Award Ford Motor Company Leadership in Health Award Metropolitan Detroit Top Doctors List – Hour Magazine Vice Chair, Pediatric Scientific Interest Group, ASBMT Annual Meeting Chair, Scientific Program, ASBMT Annual Meeting Chair, Pediatric Scientific Interest Group, ASBMT Annual Meeting
SCIENTIFIC ACTIVITIES


GRANT SUPPORT

Current
1.
U01 HL069330 (Ferrara)
Core Clinical Center of the BMT Research Network The major goal of this project is to develop innovative BMT clinical trials in a cooperative group setting. Investigator-Initiated Clinical Research Grant
Addition of Etanercept and Extracorporeal Photopheresis to standard GVHD prophylaxis in patients undergoing reduced intensity unrelated donor hematopoietic stem cell transplant The major goal of this project is to conduct a clinical trial testing whether augmenting standard GVHD prophylaxis with etanercept and extracorporeal photopheresis will reduce the incidence of lethal GVHD and avoid prolonged steroid exposure in older patients undergoing reduced intensity unrelated donor BMT. Funding from Therakos, Inc provides supplies and covers cost of ECP treatments for study patients. Funding from Amgen, Inc provides etanercept sufficient to treat study patients. 5 P01 CA 039542 (Ferrara)
Cellular and Molecular Studies in BMT – Program Project Grant Project 3: GVHD Clinical Trials and Biomarkers The major goals of this project are to (1) conduct a phase II clinical trial using the HDACi, vorinostat, in addition to standard immunosuppression to prevent GVHD in related donor reduced intensity transplantation, (2) to develop biomarkers specific to GVHD target organs (skin and GI tract), (3) to validate eight newly discovered candidate proteins as biomarkers for the diagnosis, prognosis, and prediction of systemic acute GVHD, and (4) to optimize predictive, diagnostic, and prognostic biomarker panels using validated combinations of target organ specific and systemic biomarkers and to analyze their value in new clinical trials. Core C: Clinical Sample Database and Proteomics The services provided by Core C include (1) collect, process, and distribute patient derived research samples, (2) collect data for, quality control, and maintain the integrated comprehensive patient database, and (3) provide cutting edge proteomic analysis technology U10 CA98543 (Mody)
National Childhood Cancer Foundation (NIH/NCI)
Children’s Oncology Group This grant funds a multi-institutional effort aimed at improving our understanding of the nature of pediatric cancers and the treatment thereof. Role: Co-Investigator R34 HL105776 (Levine)
Phase II Study of a Novel GVHD Prevention Strategy: Etanercept and Photopheresis The overall goals of this project are to (1) test the hypothesis that augmenting standard GVHD prophylaxis with a tumor necrosis factor (TNF)-inhibitor, etanercept, and induction of Treg by ECP, will be a clinically effective GVHD prevention strategy and (2) correlate cellular and plasma biomarkers of GVHD with clinical outcomes. Role: PI K23 CA088930 (Levine)
Cellular Immunotherapy for High-Risk Hematologic Malignancy after Allogeneic BMT The major goals of this project were to determine the optimal conditions for prophylactic donor leukocyte infusions to prevent relapse for high-risk hematologic malignancies following allogeneic hematopoietic stem cell transplantation Role: PI Doris Duke Charitable Foundation (Ferrara)
Novel Strategies to Improve Allogeneic Bone Marrow Transplant (BMT) The major goals of this project are to evaluate the role of inflammatory cytokines and antigen presentation cells in the pathogenesis of GVHD and develop new therapeutic approaches targeting these pathways. Role: Co-investigator FD-R-002397 (Levine)
FDA Orphan Drug Grant Treatment of GVHD Using Enbrel The specific aims are 1) to evaluate the response rate of etanercept when administered with steroids for the treatment of biopsy proven aGVHD, and 2) to analyze plasma cytokine levels in patients with aGVHD before and after treatment with etanercept and to correlate these laboratory endpoints with clinical outcomes during the trial. HHSN268200425220C Under BAA-RM-04-23 (Reaman)
Re-engineering the Clinical Research Enterprise: Feasibility of Integrating and Expanding Clinical Research Networks The major goals of this project are to develop a collaborative effort between two clinical trials networks, the Pediatric Blood and Marrow Transplant Consortium and the Children’s Oncology Group, in order to enhance the availability, safety, and efficacy of pediatric blood and marrow transplantation and to advance the science and application of BMT through coordinated development of research concepts and collection of data between the PBMTC, the COG, and related networks in BMT. Role: Steering Committee Member 5 P01 CA 039542 (Ferrara)
Cellular and Molecular Studies in BMT – Program Project Grant Project 3: Cytokine Modulation Strategies in Clinical Allogeneic BMT The major goals of this project are to (1) conduct a phase II clinical trial using etanercept in combination with standard GVHD prophylaxis in recipients of myeloablative unrelated donor BMT, (2) to develop biologic and genetic predictive markers of outcomes after unrelated donor BMT, and (3) to determine the role of TNF in dendritic cell activation and keratinocyte apoptosis that occurs in GVHD skin. University of Michigan Clinical Research Initiative (Geiger/Levine)
Dendritic Cell Vaccine Therapy of Sarcoma Patients Post Stem Cell Transplantation The major goals of this project are to evaluate the ability of tumor lysate-pulsed DC vaccine to augment the anti-tumor immune response in pediatric and young adult patients with sarcomas after autologous HSCT.
Pending

1.
R21 (Ferrara)
Plasma Biomarkers of Acute Graft Versus Host Disease The goal of this project is to validate an algorithm. There are currently no laboratory tests to predict the outcome of treatment of graft versus host disease (GVHD) the major lethal complication of allogeneic bone marrow transplantation. We have recently discovered an algorithm using six serum biomarker values that we have previously validated that predicted both day 28 response to treatment and mortality at day 180 from onset. This project will validate that algorithm by measuring all six biomarkers in a second group of 200 patients who have recently participated in a multicenter clinical trial for newly diagnosed acute GVHD. LLS-SCOR (Ferrara)
Ann Arbor-Regensburg Intestinal Graft Versus Host Disease Alliance (ARIA) The overarching goal of these 4 projects of this center is to accelerate the development of new therapies for graft versus host disease (GVHD) of the gastrointestinal (GI) tract, the major complication of allogeneic bone marrow transplantation (BMT) Role: Project Leader U54 (Renbarger)
NIH/NICHD Indiana University Center for Pediatric Pharmacology Biomarkers of Sinusoidal Obstructive Syndrome in Children Undergoing Hematopoietic Stem Cell Transplantation The goals of this project are to evaluate genomic biomarkers, to validate proteomic biomarkers, and to develop a model using combinations of biomarkers that best predict risk for SOS. Role: Project 2 Subcontract Co-Investigator
CERTIFICATION AND LICENSURE
Medical licensure
1990

Certification
1990
Sub-Board of Pediatric Hematology/Oncology
MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES
1989
American Society of Blood and Marrow Transplantation Board of Directors, American Society of Blood and Marrow Transplantation CLINICAL ACTIVITIES
1995-
Attending physician, Bone Marrow Transplantation Attending physician, Pediatric Hematology/Oncology
TEACHING ACTIVITIES

University of Michigan Medical School
1997-1998
M1 component: “Physical Examination, Introduction to the Patient,” Team instructor M1 component: Host Defense Systems: “Bone Marrow and Organ Transplantation” M1 component “Humoral Immunodeficiencies” M1 component: Host Defense Systems: “Cellular Immunodeficiencies M3 component: “Fluids and Electrolytes, Introduction to the Patient” M2 component: Hematology: “Macrocytic Anemia” M2 component: Hematology: “Myeloid Cell Disorders” Pharm 621: Translational Pharmacology: “Issues in Pediatric Clinical Trial Design” University of Michigan Health System Aug 1996 “Myelodysplastic Syndrome: Issues in Pediatrics,” Pediatric Grand Rounds, University of Michigan Medical Center “Research Advances in Sickle Cell Disease,” Michigan Sickle Cell Family Support Group, Ann Arbor “Sickle Cell Disease: From Screening to Cure,” Pediatric Grand Rounds, University of Michigan Medical Center “Childhood Leukemia,” University of Michigan School of Dentistry “Umbilical Cord Blood Transplantation,” The 11th Annual Modern Perinatal Problems: An Update for the Obstetrical Care Provider, University of Michigan Medical School “Donor Lymphocyte Infusions: Now and the Future,” Cancer Center Symposium: Bone Marrow Transplantation: Immunotherapy in the 21st Century, University of Michigan Medical School “Introduction to Bone Marrow Transplantation,” University of Michigan Pediatric House Officers Noon Conference “Cellular Immunotherapy for Bone Marrow Transplant Recipients,” Pediatric Grand Rounds, University of Michigan “Clinical Investigation,” Session Moderator, 15th Annual Pediatric Research Symposium, University of Michigan “Morbidity and Mortality,” Leukemia and Lymphoma Research Conference, University of Michigan, (3-4 times each year)
MENTORING ACTIVITIES

1999-2003
Current Position: Assistant Professor of Medicine, Division of Rheumatology and Immunology, Brigham and Women’s Hospital Project: Adherence with Primary and Secondary Prophylaxis in Patients with Hemophilia Current Position: Assistant Professor of Pediatrics, Co-Director, Duke Comprehensive Hemostasis and Thrombosis Center Project: Diagnosis of GVHD by Flow Cytometry Current Position: House Officer, Otolaryngology, University of Michigan Project: Diagnosis & Treatment of Chronic GVHD Current Position: Assistant Professor of Pediatrics, Division of Hematology/Oncology, University of Michigan Sung Choi, MD, Project: Diagnosis & Treatment of Acute GVHD Current Position: Assistant Professor of Pediatrics, Division of Hematology/Oncology, University of Michigan Changying Liu, Ph.D.: Dissertation Committee “Parametric Models for Optimal Treatment Schedule Finding in Adaptive Early-Phase Clinical Trials”, School of Public Health Current Position: Principal Statistical Scientist, PPD, Inc. Jin Zhang, doctoral candidate. Dissertation Committee
EXTRAMURAL INVITED PRESENTATIONS:
Feb 1995
"Molecular Differences between the HLA Class I Loci," Department of Pediatrics, St. Jude Children's Research Hospital, Memphis, Tennessee "Molecular Differences between the HLA Class I Loci," Division of Hematology/Oncology, Emory University, Atlanta, Georgia Peripheral Blood Stem Cell Transplantation,” Michigan Association of Pediatric Oncology Nurses, Ann Arbor, Michigan “Sickle Cell Anemia,” First Annual African American Health Summit, Ypsilanti, Michigan “Donor Leukocyte Infusions to Treat Post-Transplant Relapses in Children,” Pediatric Blood and Marrow Transplant Consortium, San Francisco, California “Allogeneic Peripheral Blood Stem Cell Transplantation in Children,” Pediatric Blood and Marrow Transplant Consortium, San Francisco, California “Donor Leukocyte Infusions to Treat Post-BMT Relapse in Children,” Michigan Association of Pediatric Oncology Nurses, Ann Arbor, Michigan “Donor Leukocyte Infusions to Treat Post-BMT Relapse in Children,” Michigan Pediatric Hematologists Club, Novi, Michigan “Donor Leukocyte Infusions to Treat Post-Transplant Relapses in Children,” Divisions of Hematology/Oncology- Internal Medicine and Pediatrics, Vanderbilt University, Nashville, Tennessee “A New Era for Sickle Cell Disease,” First Annual Paul Williams Foundation Sickle Cell Benefit, Canton, Michigan “Bone Marrow Transplantation,” Pediatric Grand Rounds, Hurley Medical Center, Flint, Michigan “Bone Marrow Transplantation for Congenital Neutropenia,” National Neutropenia Network, Chicago, Illinois “Adoptive Immunotherapy following Bone Marrow Transplantation,” Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania “Cellular Immunotherapy for Bone Marrow Transplant Recipients,” Pediatric Medical Grand Rounds, University of Alabama, Birmingham, Alabama “Donor Leukocyte Infusions,” Oncology Nursing Society, IBMTR/ABMTR Tandem BMT Meetings, Keystone, Colorado “Issues in Bone Marrow Transplantation for Congenital Neutropenia,” SCNIR Research Meeting, Orlando, Florida “Reduced Intensity Conditioning, Cytokines, and Graft-versus-Host Disease,” Keynote presentation, 3rd International Workshop on Non-myeloablative Stem Cell Transplantation, Captiva Island, Florida “Clinical Results: Cord Blood or Alternative Donor Transplantation,” Session Co-Chair, American Society of Hematology Meeting, Philadelphia, Pennsylvania “Aggressive Non-Hodgkin’s Lymphoma,” Session Chair, 18th International Conference: Lymphoma.the Next Questions 2004, San Juan, Puerto Rico “Autologous versus Allogeneic Transplantation for Lymphoblastic Lymphoma,” Invited presentation, 18th International Conference: Lymphoma.the Next Questions 2004, San Juan, Puerto Rico “Acute GVHD: New Strategies for Prevention, Diagnosis and Treatment,” Pediatric Seminar, MD Anderson Cancer Center, Houston, Texas “Bone Marrow Transplantation,” 11th Annual Memorial Strandhagen Lecture, Bon Secours Hospital, Grosse Pointe, Michigan “Pediatric Blood and Marrow Transplantation,” Session Chair, International Scientific Conference on Pediatric Blood and Marrow Transplantation, Vancouver, Canada “Autologous versus Allogeneic Transplantation for Lymphoblastic Lymphoma,” Invited presentation, International Symposium on Allogeneic Transplantation in Lymphoma, Udine, Italy “Clinical Care: Transplantation Regimen Toxicities and Engraftment,” Session Co-Chair, American Society of Hematology Meeting, Atlanta, Georgia “Guidelines for Staging and Grading Acute GVHD in Children,” Children’s Oncology Group, Chicago, Illinois “Improving Outcomes Through Clinical Research,” 3rd Annual Great Lakes Blood Cancer Conference, Troy, Michigan “Pediatric Committee Presentation,” Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium, Ann Arbor, Michigan “Acute GVHD: Novel Strategies for Prevention, Diagnosis, and Treatment,” 5th National Bone Marrow Transplantation and Stem Cell Therapies Congress, Turkish Society of Hematology, Antalya, Turkey “New Approaches to Acute GVHD,” Bone Marrow Transplant and Cellular Therapy Seminar, St Jude Children’s Research Hospital, Memphis, Tennessee “Stem Cells: More Uses,” 35th Annual Current Topics in Blood Banking, Ann Arbor, Michigan “New Treatments for GVHD”, Nagoya Conference Zenyaku, Nagoya, Japan “Advances in Acute GVHD”, Hyogo College of Medicine, Osaka, Japan “Acute GVHD: Novel Strategies for Prevention, Diagnosis, and Treatment,” Plenary Session, 31st Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation, Sapporo, Japan “Treatment vs Transplant for Challenging Hematological Disorders,” Session Chair, American Society of Blood and Marrow Transplantation Annual Meeting, Tampa, Florida “Kostmann’s Syndrome,” American Society of Blood and Marrow Transplantation Annual Meeting, Tampa, Florida “Congenital Neutropenia: Making the Decision to Transplant,” National Neutropenia Network Annual Family Conference, Ypsilanti, Michigan “Principles of Hematopoietic Stem Cell Transplant,” 144th Michigan State Medical Society Annual Scientific Meeting, Troy, Michigan “Clinical Care - Transplantation Regimen Toxicities and Engraftment: Novel Reduced Intensity Protocols,” Session Co-Chair, American Society of Hematology Meeting, New Orleans, Louisiana “Principles of Bone Marrow Transplant,” Great Lakes Cancer Institute, Clarkston, Michigan “Acute GVHD: New Approaches to Diagnosis and Prevention,” Invited seminar, University of Utah BMT Program, Salt Lake City “Translational Trials in Acute GVHD,” Invited seminar, Pediatric BMT Program, Washington University, St. Louis, Missouri “Graft-vs-Host Disease,” Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow 2010, New York, New York “Translational Research in GVHD,” HSCT Staff Development Conference, Dana Farber Cancer Institute, Harvard University, Boston, Massachusetts “Analysis of Biomarkers for GVHD in Clinical Trials,” Invited speaker, Clinical Trials Symposium, American Society of Blood and Marrow Transplantation Annual Meeting, Honolulu, Hawaii “Translational Research in Acute GVHD,” Invited Seminar, Children’s Hospital of Pennsylvania, Philadelphia “Challenges in Diagnosis and State of the Art in the Treatment of Acute GVHD,” Invited Speaker, Avances en el diagnóstico y manejo de le enfermedad de injerto contra huésped, Hospital Universitario Austral, Buenos Aires, Argentina “Improving Outcomes in Bone Marrow Transplantation,” Great Lakes Cancer Institute, Clarkston, Michigan “Principles of Bone Marrow Transplantation for Congenital Neutropenia,” National Neutropenia Network Annual Family Conference, Ypsilanti, Michigan “Clinical Applications for Biomarkers of Acute and Chronic Graft-Versus-Host Disease,” Chair, Plenary Session, American Society of Blood and Marrow Transplantation Annual Meeting, San Diego, California “GVHD Biomarkers in Clinical Trials,” Plenary Session, American Society of Blood and Marrow Transplantation Annual Meeting, San Diego, California “Clinical Applications of GVHD Biomarkers” and “New Approaches to the Treatment of Acute GVHD,” GVHD Symposium: State of the Art, Bangkok, Thailand “Extracorporeal Photopheresis for GVHD,” Nagoya International Blood and Marrow Transplantation Symposium, Nagoya, Japan “Clinical Applications of GVHD Biomarkers,” Kyushu University School of Medicine, Fukuoka City, Japan “Clinical Applications of GVHD Biomarkers,” Saitama Medical Center Jichi Medical University, Tokyo, Japan
PATENTS:

U.S. Provisional Patent Application 61/542,630, filed October 3, 2011
“METHODS FOR DETECTING GRAFT-VERSUS-HOST DISEASE”
Role: Co-inventor
This invention relates to methods for detecting graft-versus-host disease (GVHD) using biomarkers associated with acute GVHD to detect and predict GVHD. In additional aspects, the invention relates to methods using biomarkers to predict outcome in subjects with acute GVHD.
COMMITTEE AND ADMINISTRATIVE SERVICE
International

Multicenter Prospective Donor Leukocyte Infusion Consortium
Center for International Blood & Marrow Transplant Research
Severe Chronic Neutropenia International Registry Advisory Board
Member, Safety and Therapeutics Committee
National

Pediatric Blood and Marrow Transplant Consortium
Principal Investigator, University of Michigan Strategy Group Co-Chair, Stem Cell Sources Executive Committee, Member at Large, 2001-2002 Executive Committee, Vice Chair (appointed 2002; elected 2003) Executive Committee, ex officio member, by appointment Children’s Oncology Group
Vice Chair, Hematopoietic Stem Cell Transplantation Committee

2001, 2003
National Institute of Neurological Diseases and Stroke:
Member, Special Emphasis Panel on Clinical Research Ronald McDonald House, Ann Arbor, MI
National Cancer Institute, Center for Bioinformatics
Bone Marrow Transplant Common Data Elements Committee National Heart, Lung, and Blood Institute, Special Workshop on Sickle Cell
Disease

Co-Chair, Bone Marrow Transplant Subcommittee National Marrow Donor Program
Patient and Donor Safety Committee (Vice Chair, 2012- ) National Cancer Institute, 1st International Workshop on the Biology, Prevention,
and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell

Transplantation
Food and Drug Agency, Center for Drug Evaluation and Research

University of Michigan
1996-2001
Pediatric Critical Care Unit Joint Practice Committee Member, Data and Safety Monitoring Board, University of Michigan Cancer Center
Mott Children’s Hospital Executive Committee Protocol Review Committee, University of Michigan Cancer Center
PUBLICATIONS
1. Porter TL, Levine JE, Dinneen M: Shifts of dependency in the resolution of folie á deux. Br J Psych 162:704-

2. Levine JE and Yang SY: SSOP typing of the Tenth International Histocompatibility Workshop reference cell
lines for HLA-C alleles. Tissue Antigens. 44:174-183, 1994.
3. Levine JE and Yang SY: Allelic frequencies of the HLA-B17 antigen group: Comparative analysis by serology,
IEF, and PCR-SSOP typing. Tissue Antigens 46:368-373, 1995.
4. Levine JE, Cohen A, MacQueen M, Martin M, Giardina PJ: Sensorimotor neurotoxicity associated with high
dose deferoxamine treatment. J Ped Hem Onc 19:139-141, 1997.
5. Levine JE, Wiley J, Kletzel M, Yanik GA, Hutchinson RJ, Neudorf S: Cytokine mobilized allogeneic peripheral
blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD. Bone Marrow Transplantation. 25:13–18, 2000. 6. Zeidler C, Barak Y, Barriga F, Bolyard AA, Bonilla MA, Boxer L, Cornu G, Cowan M, Dale DC, Flood T, Freedman M, Gadner H, Mandel H, O’Reilly R, Ramenghi U, Reiter A, Skinner R, Vermylen C, Welte K,
Levine JE. Stem cell transplantation in patients with severe congenital neutropenia without evidence of
leukemic transformation. Blood. 95:1195-1198, 2000.

7. Yanik GA, Levine JE, Ratanatharathorn V, Dunn R, Ferrara JLM, and Hutchinson RJ. Tacrolimus (FK506)
and methotrexate as prophylaxis for acute graft versus host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplantation. 26:161-167, 2000.
8. Ratantharathorn V, Carson E, Reynolds C, Ayash LA, Yanik GA, Silver SM, Levine JE, Ferrara JLM, Uberti
JP. Anti-CD20 chimeric monoclonal antibody therapy for immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Annals of Internal Medicine. 133:275-279, 2000.
9. Williams DA, Tao W, Yang F, Kim C, Gu Y, Mansfield P, Levine JE, Petryniak B, Derrow CW, Harris C, Jia B,
Zheng Y, Ambruso D, Lowe JB, Atkinson S, Dinauer MC, Boxer L. A dominant negative mutation of the hematopoietic-specific RhoGTPase, Rac 2, is associated with a human phagocyte immunodeficiency. Blood. 96:1646-1654, 2000.
10. Beckman RA, Siden R, Yanik GA, Levine JE. Continuous octreotide infusion for the treatment of secretory
diarrhea due to acute intestinal graft-versus-host-disease in a small child. J Ped Hem Onc. 22:344-50, 2000.
11. Collins RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M,
Parker P. Donor leukocyte infusions in acute lymphoblastic leukemia. Bone Marrow Transplantation. 26:511-16, 2000.
12. Petty EM, Yanik GA, Hutchinson RJ, Alter BP, Schmalstieg FC, Levine JE, Ginsburg D, Robillard JE, Castle
VP. Successful bone marrow transplantation in Schimke immunoosseous dysplasia: Report of a case and
literature review. J Pediatr. 137:882-6, 2000.

13. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, Porter D, Giralt S, Levine JE, Drobyski W,
Barrett J, Horowitz M, Collins R. Donor leukocyte infusions in multiple myeloma. Bone Marrow Transplantation. 26:1179-84, 2000.
14. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mulé
JJ. Vaccination of pediatric solid tumors with tumor lysate-pulsed dendritic cells expands specific T cells and mediates tumor regression. Cancer Research. 61:8513-9, 2001.
15. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski W, Barrett AJ, Porter DL, Giralt S,
Leis J, Johnson M, Horowitz M, Collins, RH. A prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies following allogeneic stem cell transplantation. Journal of Clinical Oncology. 20:405-412, 2002. 16. Yanik GA, Levine JE, Sisson JC, Shulkin BL, Matthay KK, Shapiro B, Hubers D, Hutchinson RJ. Pilot study of
iodine-131--metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem cell support for the treatment of neuroblastoma. Journal of Clinical Oncology. 20:2142-2149, 2002.
17. Levine JE, Boxer LA. Clinical applications of hematopoietic growth factors in pediatric oncology. Current
Opinion in Hematology. 9:222-227, 2002.
18. Levine JE and Collins RH. Critical factors in optimizing graft-versus-leukemia effect for relapsed leukemias. J
Clin Oncol. 20:2756-7, 2002. Letter.
19. Levine JE, Harris RE, Loberiza FR, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM. A
comparison of allogeneic and autologous bone marrow transplant for lymphoblastic lymphoma. Blood. 101:2476-2482, 2003.
20. Levine JE, Uberti JP, Ayash L, Reynolds C, Ferrara JLM, Silver SM, Braun T, Yanik GA, Hutchinson RJ,
Ratanatharathorn V. Lowered intensity preparative regimen for allogeneic stem cell transplantation delays acute GVHD but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant. 9:189-197, 2003.
21. Prasannan L, Flynn JT, Levine JE. Acute renal failure following deferoxamine overdose corrected with
hemodialysis. Pediatric Nephrology, 18:283-285, 2003.

22. Braun TM, Levine JE, Ferrara JLM. Determining a maximum tolerated cumulative dose: Dose reassignment
within TITE-CRM. Controlled Clinical Trials. 24:669-81, 2003.
23. Pulsipher MA, Levine JE, Hayashi RJ, Chan KW, Anderson P, Duerst R, Osunkwo I, Fisher V, Horn B, Grupp
SA. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium experience (PBMTC) 1996-2003. Bone Marrow Transplantation. 35:361-7, 2005.
24. Choi SW, Boxer LA, Pulsipher MA, Roulston D, Hutchinson RJ, Yanik GA, Cooke KR, Ferrara JLM, Levine
JE. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic
transformation. Bone Marrow Transplantation. 35:473-477, 2005.

25. Alexander BM, Wechsler D, Braun TM, Levine JE, Herman J, Yanik GA, Hutchinson RJ, Pierce LJ. Utility of
cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 2005, 63:1191-1196. 26. Uberti JP, Ayash L, Ratanatharathorn V, Silver SM, Reynolds C, Becker M, Reddy P, Cooke KR, Yanik GA, Whitfield J, Jones D, Hutchinson RJ, Ferrara JLM, Levine JE. Phase I/II Trial on the use of etanercept and
methylprednisolone as primary treatment for acute graft-vs-host disease (aGVHD). Biol Blood Marrow Transplant. 11:680-7, 2005.
27. Levine JE and Ferrara JLM. Graft-versus-host disease in the 21st century: New perspectives. Seminars in
Hematology, 43:1-2, 2006. Review.
28. Porter D and Levine JE. GVHD and GVL after donor leukocyte infusion. Seminars in Hematology, 43:53-61,

29. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Use of G-CSF in matched sibling donor
pediatric allogeneic transplantation: A consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer. 46:414-21, 2006. 30. Eggleston BS, Patience M, Edwards S, Adamkiewicz T, Buchanan G, Davies SC, Dickerhoff R, Donfield S, Feig SA, Giller RH, Haight A, Horan J, Hsu L, Kamani N, Lane P, Levine JE, Margolis D, Moore TB, Ohene-
Frempong K, Redding-Lallinger R, Roberts IAG, Rogers ZR, Sanders JE, Scott JP, Sleight B, Thompson AA,
Sullivan KM, and Walters MC for the multicenter study of HCT for SCA. Effect of myeloablative bone marrow
transplantation on growth in children with sickle cell anemia: Results of the multicenter study of hematopoietic
cell transplantation for sickle cell anemia. British J Haematol. 136:673-6, 2007.

31. Mischler M, Fleming GM, Shanley TP, Madden L, Levine J, Castle V, Filipovich AH, Cornell TT. Epstein Barr
virus induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: A mimicker of sepsis in the pediatric intensive care unit. Pediatrics. 119:e1212-8, 2007.
32. Savona MR, Newton D, Frame D, Levine JE, Mineishi S, Kaul DR. Low dose cidofovir treatment of polyoma
BK virus associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant. 39:783-7, 2007.
33. Chao MM, Levine JE, Ruiz RE, Kohlmann WK, Bower MA, Petty EM, Mody RJ. Malignant triton tumor in a
patient with Li-Fraumeni syndrome and a novel TP53 mutation. Pediatr Blood Cancer. 49:1000-4, 2007.
34. Ferrara JLM, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine JE, Schultz K, Appelbaum F,
Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 13:1268-85, 2007. 35. Frangoul H, Nemecek ER, Billheimer D, Pulsipher MA, Khan S, Woolfrey A, Manes B, Cole C, Walters MC, Ayas M, Ravindranath Y, Levine JE, Grupp SA. A prospective study of G-CSF primed bone marrow as a
stem cell source for allogeneic bone marrow transplant in children: A Pediatric Blood and Marrow Transplant
Consortium (PBMTC) Study. Blood. 110:4584-7, 2007.

36. Chao MM, Levine JE, Cooling L, Cooke KR, Hutchinson RJ, Yanik GA. Successful treatment of refractory
immune hemolysis following unrelated cord blood transplant with Campath. Pediatr Blood Cancer. 50:917-9, 2008.
37. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley
D, Krijanovski O, Reddy P, Yanik G, Ferrara, JLM. Etanercept plus methylprednisolone as initial therapy for acute GVHD. Blood. 111:2470-2475, 2008.
38. Ozkaynak MF, Sahdev I, Gross TG, Levine J, Cheerva AC, Richards MK, Rozans MK, Shaw PJ, Kadota RP.
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors – A Pediatric Blood and Marrow Transplant Consortium study. J Ped Hem Onc. 30:204-209, 2008. 39. Kitko CL, Paczesny S, Yanik G, Braun T, Jones D, Whitfield J, Choi SW, Hutchinson RJ, Ferrara JLM, Levine JE. Plasma elevations of tumor necrosis factor receptor-1 at day 7 post allogeneic transplant correlate
with graft versus host disease severity and overall survival in pediatric patients. Biol Blood Marrow Transplant.
40. Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S, Krijanovski O, Jones D, Whitfield J, Cooke K, Hutchinson RJ, Ferrara JLM, Levine JE. Change in plasma tumor necrosis factor receptor 1 levels in the first
week post-myeloablative allogeneic transplant correlates with severity and incidence of GVHD and survival.
Blood. 112:1539-1542, 2008.

41. Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin, N, Fort J, Loberiza F, Porter DL, Giralt S,
Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz MM, Collins RH. Donor leukocyte infusions to treat
hematologic malignancy relapse following allogeneic stem cell transplantation in a pediatric population. Bone
Marrow Transplant
. 42:201-205, 2008.

42. Levine JE, Blazar BR, DeFor T, Ferrara JLM, Weisdorf DJ. Long-term followup of a phase I/II randomized,
placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant. 14:1017-1021, 2008.
43. Yanik GA, Ho VT, Levine JE, White ES, Braun T, Antin JH, Whitfield J, Custer J, Jones D, Ferrara JLM,
Cooke KR. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation. Blood. 112:3073-4081, 2008.PMCID: PMC3045267 44. Paczesny S, Krijanovski O, Braun TM, Choi S, Clouthier SG, Kuick R, Misek, DE, Cooke KR, Kitko CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine JE, Hanash SM, Ferrara JLM. A biomarker
panel for acute graft versus host disease. Blood. 113:273-278, 2009. (plenary paper)

45. Peres E, Khaled Y, Krijanovski OI, Mineishi S, Levine JE, Kaul DR, Riddell J. Mycobacterium chelonae
necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: Report of clinical response to treatment with tigecycline. Transplant Infectious Disease 11:57-63, 2009.
46. Ferrara JLM, Levine JE, Reddy PR, Holler E. Graft-versus-host disease. Lancet. 373:1550-61, 2009. Review.
47. Khaled YA, Abidi MH, Janakiraman N, Kato K, Levine JE, Reddy P, Medina M, Peres E, Hanbali A, Mineishi
S. Outcomes after autologous stem cell transplantation in 101 consecutive African Americans with multiple myeloma. Bone Marrow Transplant. 43:845-51, 2009. 48. Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, DiFronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE. Etanercept, mycophenolate, denileukin or
pentostatin plus corticosteroids for acute graft vs. host disease: A randomized phase II trial from the BMT
CTN. Blood. 114:511-7, 2009.

49. Sisler IY, Koehler E, Koyama T, Domm JA, Ryan R, Levine JE, Pulsipher MA, Haut PR, Schultz KR, Taylor
DS, Frangoul HA. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplant for children with AML beyond first complete remission: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Biol Blood Marrow Transplant. 15:1620-7, 2009.
50. Peres E, Braun T, Krijanovski O, Khaled Y, Levine JE, Yanik G, Kato K, Mineishi S. Reduced intensity versus
full myeloablative stem cell transplant for advanced CLL. Bone Marrow Transplant. 44:579-83, 2009.
51. Paczesny S, Braun T, Levine J, Ferrara JLM. Plasma biomarkers in GVHD: a new era? Biol Blood Marrow
Transplant. 15 supp 1:33-38, 2009. Review.
52. Parker CJ, Brodsky RA, Levine JE. Treatment vs. transplant for challenging hematological disorders. Biol
Blood Marrow Transplant. 15 supp 1:72-78, 2009. Review.
53. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, Olsen S, Choi SW, Wang H, Faca V,
Pitteri S, Zhang Q, Chin A, Kitko C, Mineishi S, Yanik G, Peres E, Hanauer D, Wang Y, Reddy P, Hanash S, Ferrara JLM. Elafin is a biomarker of graft versus host disease of the skin. Science Translational Medicine.
54. Peres E, Levine JE, Khaled YA, Rami I, Braun TM, Krijanovski OI, Mineishi S, Abidi MH. Cardiac
complications in patients undergoing a RIC HSCT. Bone Marrow Transplant. 45:149-52, 2010. 55. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, Buchanan GR, Bunin N, Dickerhoff R, Giller R, Haut PR, Horan J, Hsu LL, Kamani N, Levine JE, Margolis D, Ohene-Frempong K,
Patience M, Redding-Lallinger R, Roberts IAG, Rogers ZR, Sanders JE, Scott JP, Sullivan KM for the
multicenter study of BMT for sickle cell disease. Pulmonary, gonadal and central nervous system status after
bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 16:263-72, 2010.

56. Jacobson PA, Huang J, Wu J, Kim M, Logan B, Alousi A, Grimley M, Bolaños-Meade J, Ho V, Levine JE,
Weisdorf D. Mycophenolate pharmacokinetics and association with response to acute graft vs host disease (GVHD) treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant, 16:421-9, 2010. 57. Choi SW, Levine JE, Ferrara JLM. Pathogenesis and management of graft-versus-host disease. Immunol
Allergy Clin North Am, 30:75-101, 2010. Review. 58. Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, Bickley D, Braun TM, Jang PS, Lowler KP, Jones DM, Choi SW, Reddy P, Mineishi S, Levine JE, Ferrara JL, Paczesny S. Frequency of
CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute
graft-versus-host-disease. Biol Blood Marrow Transplant, 16:907-14, 2010.
59. Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J,
Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 16:1467-503, 2010. (all authors contributed equally) 60. Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bolaños-Meade J, Weisdorf D. Graft-versus-host disease
treatment: predictors of survival. Biol Blood Marrow Transplant, 16:1693-1699, 2010.
61. Choi SW, Levine JE. Indications for hematopoietic cell transplantation for children with severe congenital
neutropenia. Pediatr Transplant, 14:937-9, 2010. Editorial. 62. Kitko CL, Levine JE, Matthews DC, Carpenter PA. Successful unrelated donor cord blood transplantation for
Glanzmann’s thrombasthenia. Pediatr Transplant, 15:e42-6, 2011. 63. Levine JE. Implications of TNF-α in the pathogenesis and management of GVHD. Int J Hematol, 93: 571-7,
64. Gilman AL, Jacobsen C, Bunin N, Levine J, Goldman F, Bendel A, Joyce M, Anderson P, Rozans M, Wall
DA, MacDonald TJ, Simon S, Kadota RP. Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: A Pediatric Blood and Marrow Transplant Consortium study. Pediatr Blood Cancer, 57:506-13, 2011. 65. Rizwan R, Levine JE, DeFor T, Ferarra JLM, Weisdorf DJ, Blazar BR, Verneris MR. Peri-transplant
palifermin use and lymphocyte recovery after T-cell replete, matched related allogeneic hematopoietic cell transplantation. Am J Hematology, 86:879-82, 2011. 66. Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi SW, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S.
Clofarabine and busulfan conditioning facilitates engraftment and provides significant anti-tumor activity in
non-remission hematologic malignancies. Blood, 118:4258-64, 2011.
67. Ferrara JLM, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E,
Landfried K, Akashi K, Vander Lugt MT, Reddy P, Chin A, Zhang Q, Hanash S, Paczesny, S. Regenerating islet-derived 3 alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood, 118:6702-8, 2011. 68. Connelly JA, Choi SW, Levine JE. Hematopoietic stem cell transplantation for severe congenital neutropenia.
Current Opinion in Hematology, 19:44-51, 2012. Review. 69. Levine JE, Paczesny S, Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-
versus-host disease. Biol Blood and Marrow Transplant, 18:S116-S124, 2012. Review. 70. Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, Harris AC, Braun T, Cooke KR.
Soluble tumor necrosis factor receptor: Enbrel (etanercept) for sub-acute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood and Marrow Transplant, prepublished online 9 December 2011, doi:10.1016/j.bbmt.2011.11.031. 71. Harris AC, Ferrara JLM, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Landfried K, Akashi K, Vander
Lugt MT, Couriel DR, Reddy P, Paczesny S. Plasma biomarkers of lower gastrointestinal and liver acute graft-versus-host disease. Blood, 119:2960-2963, 2012. 72. Levine JE, Logan BR, Wu J, Alousi AM, Bolaños Meade J, Ferrara JLM, Ho VT, Weisdorf DJ, Paczesny S.
Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A Blood and Marrow Transplant Clinical Trials Network study. Blood, 119:3854-3860, 2012. 73. Kamani NR, Walters MC, Carter S, Aquino, V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher MA, Sande J, Schultz KR, Spellman S,
Shenoy S. Unrelated donor cord blood transplantation for children with severe sickle cell disease: Results of
one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood
and Marrow Transplant, prepublished online 16 February 2012, doi:10.1016/j.bbmt.2012.01.019
.
74. Choi SW, Stiff P, Cooke K, Ferrara JLM, Braun T, Kitko C, Reddy P, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE. TNF-inhibition with etanercept for graft
versus host disease prevention in high risk HCT: Lower TNFR1 levels correlate with better outcome. Biol
Blood and Marrow Transplant, prepublished online 1 April 2012, doi:10.1016/j.bbmt.2012.03.014.

Book Chapters

1. Williams JA and Levine JE. Sickle Cell Disease. In: Gellis and Kagan’s Current Pediatric Therapy, 17th
edition, eds Burg FD, Ingelfinger JR, Polin RA, Gershon AA. WB Saunders, Philadelphia, 2002.
2. Levine JE and Ferrara JLM. Practical considerations of immune reconstitution following bone marrow
transplantation. In: Current Therapy in Allergy, Immunology, and Rheumatology, 6th edition, eds. Lichtenstein LM, Busse WW, Geha RS. Mosby Press, St. Louis, 2003.
3. Hughes D and Levine JE. Therapeutic options for relapse after bone marrow transplant. In: Pediatric Stem
Cell Transplantation, ed. Mehta P. Jones and Bartlett Publishers, Sudbury, Mass, 2004.
4. Kolb HJ, Levine JE, Porter DL. Adoptive immunotherapy in stem cell transplantation. In: Graft-vs.-Host
Disease, 3rd edition, eds. Ferrara JLM, Cooke KR, Deeg HJ. Marcel Dekker Inc, New York, 2005.
5. Hughes DP and Levine JE. Cellular immunotherapeutic approaches to the HSCT patient. In: Pediatric
Hematopoietic Stem Cell Transplantation. ed. RM Kline. Marcel Dekker, Inc., New York, 2006.
6. Levine JE and Ferrara JLM. Transfusion-associated graft-versus-host disease. In: Rossi's Principles of
Transfusion Medicine, 4th edition, eds. Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG, Petrides M. AABB Press, Bethesda, Maryland, 2009. 7. Kitko C and Levine JE. Extracorporeal photopheresis for the prevention of GVHD. In: Extracorporeal
Photopheresis, eds. Greinix H, Knobler R. De Gruyter Publishers, Vienna, 2012.
INVITED EDITORSHIPS
1. Levine JE, Ferrara JLM, eds. Graft versus host disease. Seminars in Hematology, Volume 43, January 2006.
2. Davies S, Levine JE, eds. Hematopoietic stem cell transplantation 2012 education supplement. Biol Blood
and Marrow Transpl, Volume 18, Number 1, Supplement 1, January 2012.
Oral Presentations
1. Levine JE, Penza S, Topolsky D, Beatty P, Rifkin R, Giralt S, Porter DL, Drobyski WR, Horowitz MM, and
Collins RH. Prospective trial of chemotherapy plus donor leukocyte infusions (DLI) to treat relapsed advanced myeloid leukemia after related bone marrow transplantation (BMT). Presented at the American Society of Hematology, New Orleans, Louisiana, 1999.
2. Williams DA, Tao W, Yang F, Derrow C, Harris C, Kim C, Atkinson S, Mansfield P, Levine JE, Petryniak B,
Lowe J, Ambruso D, Dinauer MC, Boxer LA. Mutation of RAC-2, a hematopoietic specific RHO-GTPase, is associated with multiple neutrophil functional defects in a patient with recurrent infections. Presented at the American Society of Hematology, New Orleans, Louisiana, 1999.
3. Yanik GA, Sisson JC, Levine JE, Shulkin B, Shapiro B, Ferrara JLM, Zempel S, Spaulding S, Hutchinson RJ.
High dose 131-I MIBG infusion with myeloablative chemotherapy for the treatment of refractory neuroblastoma. Presented at the International Bone Marrow Transplant Registry Meeting, Anaheim, California, 2000.
4. Gilman A, Bunin N, Levine JE, Joyce M, Anderson P, Anderson R, Goldman F, Sambrano J, Kadota R,
Hetherington M. Dual cycle high-dose chemotherapy with stem cell rescue for recurrent medulloblastoma. Presented at the International Symposium on Pediatric Neuro-Oncology meeting, San Francisco, California, 2000.
5. Yanik GA, Sisson JC, Levine JE, Shulkin BL, Shapiro B, Ferrara JLM, Anuszkiewicz S, Bower C, Spaulding
S, Hutchinson RJ. Engraftment following high-dose 131-I MIBG infusion with myeloablative chemotherapy for the treatment of neuroblastoma. Presented at the American Society of Hematology meeting, San Francisco, California, 2000.
6. Reynolds CM, Ferrara JLM, Hutchinson RJ, Braun T, Ratanatharathorn V, Ayash L, Levine JE, Yanik GA,
Cooke K, Silver SM, Reddy P, Becker M, Uberti J. A phase I/II study of recombinant human keratinocyte growth factor (KGF) in patients with high risk hematologic malignancies undergoing mismatched related or unrelated donor transplant. Presented at the American Society of Blood and Marrow Transplantation meeting, Keystone, Colorado, 2003.
7. Pulsipher M, Levine JE, Hayashi R, Chan KW, Anderson P, Duerst R, Grupp SA. Safety and efficacy of
allogeneic PBSC collection in normal pediatric donors: the Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996-2003. Presented at the American Society of Hematology meeting, San Diego, California, 2003.
8. Uberti JP, Ayash L, Levine JE, Silver SM, Reddy P, Becker M, Reynolds C, Cooke K, Ratanatharathorn V,
Ferrara JLM. Phase I/II trial on the use of etanercept (Enbrel) and solumedrol as primary treatment for acute graft-vs-host disease (aGVHD). Presented at the American Society of Hematology meeting, San Diego, California, 2003.
9. Yanik GA, Levine JE, Ferrara JLM, Uberti JP, Ho VT, Antin JH, Cooke KR. Survival following etanercept
therapy for the treatment of idiopathic pneumonia syndrome post allogeneic stem cell transplantation. Presented at the American Society of Hematology meeting, San Diego, California, 2004. 10. Kitko CL, Paczesny S, Yanik G, Braun T, Jones D, Whitfield J, Hutchinson R, Ferrara J, Levine JE. Changes
in TNFR1 levels in the first week post-myeloablative allogeneic BMT correlate with GVHD and transplant related mortality in pediatric patients. Presented at the Midwest Society for Pediatric Research, Indianapolis, Indiana, 2006.
11. Levine JE, Kitko C, Yanik G, Braun T, Paczesny S, Mineishi S, Krijanovski O, Jones D, Cooke KR, Whitfield
J, Hutchinson RJ, Ferrara JLM. Changes in TNFR1 levels in the first week post-myeloablative HSCT correlate with severity and incidence of GVHD and 1y transplant related mortality. Presented at the American Society of Hematology meeting, Orlando, Florida, 2006.
12. Levine JE, Kitko C, Goyal R, Ferrell R, Braun T, Mullighan C, Hanauer D, Choi S, Paczesny S, Mineishi S,
Cooke KR, Jones D, Whitfield J, Yanik G, Ferrara JLM. An integrated genetic-protein analysis of the TNF-Family pathway predicts for GVHD. Presented at the American Society of Blood and Marrow Transplantation meeting, Keystone, Colorado, 2007.
13. Kitko C, Paczesny S, Yanik G, Braun T, Jones D, Whitfield J, Choi S, Hutchinson R, Ferrara J, Levine JE.
Changes in TNFR1 ratios in the first week post-myeloablative allogeneic BMT correlate with GVHD, TRM and OS in children. Presented at the American Society of Blood and Marrow Transplantation meeting, Keystone, Colorado, 2007. *winner Best Abstract Award
14. Krijanovski O, Paczesny S, Clouthier SG, Kuick R, Misek DE, Levine JE, Cooke KR, Hanash SM, Ferrara
JLM. Distinctive plasma protein profiles in patients with acute graft-versus-host disease. Presented at the European Group for Blood and Marrow Transplantation meeting, Lyon, France, 2007. 15. Paczesny S, Choi S, Braun T, Kitko C, Krijanovski O, Clouthier S, Weyand A, Bickley D, Jones D, Whitfield J, Levine JE, Ferrara J. A four protein plasma fingerprint of acute graft versus host disease (GVHD) predicts
long term survival. Presented at the American Society of Hematology meeting, Atlanta, Georgia, 2007.

16. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko C,
Krijanovski O, Reddy P, Yanik G, Ferrara JLM. Etanercept plus methylprednisolone as initial therapy for acute GVHD. Presented at the American Society of Hematology meeting, Atlanta, Georgia, 2007.
17. Yanik G, Maslak J, Connelly J, Peres E, Mineishi S, Levine J, Kaul D. Impact of broncho-alveolar lavage on
the diagnosis and management of pulmonary complications post transplant. Presented at the American Society of Blood and Marrow Transplantation meeting, San Diego, California, 2008.
18. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko C, Bickley
D, Krijanovski O, Reddy P, Yanik G, Ferrara JLM. Addition of etanercept to methylprednisolone as initial therapy for acute GVHD results in high response rates and improved survival Presented at the American Society of Blood and Marrow Transplantation meeting, San Diego, California, 2008. 19. Alousi A, Weisdorf DJ, Logan BR, Bolanos-Meade J, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE. BMT CTN 0302: A phase II randomized trial evaluating etanercept, mycophenolate
mofetil (MMF), denileukin diftitox, and pentostatin in combination with corticosteroids in 180 patients with
newly diagnosed acute graft vs. host disease (aGVHD). Presented at the American Society of Hematology
meeting, San Francisco, California, 2008.


20. Paczesny S, Levine JE, Hogan J, Crawford J, Braun T, Wang H, Faca V, Zhang Q, Pitteri S, Chin A, Choi S,
Kitko C, Krijanovski O, Reddy P, Mineishi S, Whitfield J, Jones D, Hanash S, Ferrara JL. Elafin is a biomarker of graft versus host disease of the skin. Presented at the American Society of Hematology meeting, San Francisco, California, 2008.
21. Levine JE, Adepoju LJ, Molitor M, McEwen E, Hutchinson RJ, Mody R, Mouro D, Whitfield J, Yanik GA,
Geiger JD. A pilot study of tumor lysate-pulsed dendritic cell vaccine in pediatric high-risk solid tumor patients following HCT: preliminary results. Presented at the American Society of Blood and Marrow Transplantation meeting, Tampa, Florida, 2009. *winner Best Pediatric Abstract Award 22. Krijanovski O, Krijanovski Y, Khaled Y, Cummings T, Braun T, Reddy P, Peres E, Mineishi S, Kitko C, Choi S, Yanik G, Pawarode A, Paczesny S, Levine JE. Rapid immunosuppression taper following reduced intensity
HCT from related donors is tolerable but does not improve outcomes of advanced hematologic malignancies.
Presented at the American Society of Blood and Marrow Transplantation meeting, Tampa, Florida, 2009.

23. Paczesny S, Levine JE, Hogan J, Crawford J, Braun T, Wang H, Faca V, Zhang Q, Pitteri S, Chin A, Choi S,
Kitko C, Krijanovski O, Reddy P, Mineishi S, Whitfield J, Jones D, Hanash S, Ferrara JL. Elafin is a biomarker of graft versus host disease of the skin. Presented at the American Society of Blood and Marrow Transplantation meeting, Tampa, Florida, 2009. 24. Choi S, Stiff P, Braun T, Ferrara JLM, Cooke KR, Khaled Y, Kitko C, Lay-Luskin J, Mineishi S, Nickoloff B, Paczesny S, Pawarode A, Whitfield J, Peres EM, Reddy P, Richardson J, Rodriguez T, Smith SE, Yanik GA,
Levine JE. Standard GVHD prophylaxis augmented with TNF-inhibition in alternative donor HCT: Lower
TNFR1 levels correlate with better outcomes. Presented at the American Society of Hematology meeting,
New Orleans, Louisiana, 2009.

25. Magenau JM, Qin X, Tawara I, Rogers CE, Schlough M, Bickley D, Yang PS, Braun TM, Lowler K, Jones DM, Choi SW, Mineishi S, Levine JE, Ferrara JLM, Paczesny S. Frequency of CD4+CD25hiFOXP3+ regulatory T
cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host disease. Presented at
the American Society of Hematology meeting, New Orleans, Louisiana, 2009.

26. Harris AC, Mageneau J, Braun T, Kitko CL, Choi SW, Ferrara JLM, Mineishi S, Pawarode A, Peres, E, Reddy P, Yanik G, Levine JE. Extramedullary relapse in acute leukemia following allogeneic hematopoietic stem cell
transplantation: incidence, risk factors and outcomes. Presented at the American Society of Blood and
Marrow Transplantation meeting, Orlando, Florida, 2010.

27. Paczesny S, Bickley D, Choi S, Crawford J, Braun T, Pitteri S, Hogan J, Reddy P, Hanash S, Ferrara J, Levine JE. A five biomarker panel predicts acute graft-versus-host disease. Presented at the European
Group for Blood and Marrow Transplantation meeting, Vienna, Austria, 2010.
* Winner, Best Abstract Award,
Presidential Symposium.
28. Paczesny S, Braun T, Vander Lugt M, Harris A, Fiema B, Hernandez J, Choi S, Kitko C, Magenau J,Yanik G, Peres EM, Pawarode A, Mineishi S, Whitfield J, Jones D, Couriel D, Reddy P, Hanash S, Ferrara JLM,
Levine JE. A three biomarker panel at day 7 and 14 can predict development of grade II-IV acute graft-
versus-host disease. Presented at the American Society of Hematology meeting, Orlando, Florida, 2010.
29. Mineshi S, Magenau J, Tobai H, Pawarode A, Peres EM, Reddy P, Kitko C, Choi S, Erba HP, Kujawski L, Yanik G, Ferrara J, Levine JE. Allogeneic hematopoietic stem cell transplantation with clofarabine/busulfan x
4 (CloBu4) conditioning exhibits significant anti-tumor activity in non-remission hematologic malignancies,
especially AML. Presented at the American Society of Hematology meeting, Orlando, Florida, 2010.
30. Harris AC, Ferrara JLM, Levine JE, Braun T, Hogan J, Crawford J, Pitteri S, Wang H, Chin A, Zhang Q,
Granger J, Vander Lugt M, Byersdorfer C, Magenau J, Gomez A, Choi S, Kitko C, Yanik G, Peres E, Pawarode A, Mineishi S, Reddy P, Couriel DR, Hanash S, Paczesny S. Reg3α is a biomarker of graft versus host disease of the gastrointestinal tract. . Presented at the American Society of Blood and Marrow Transplantation meeting, Honolulu, Hawaii, 2011. 31. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ho VT, Weisdorf DJ, Paczesny S. GVHD
biomarkers measured during treatment independently predict response to therapy and survival: A Blood and Marrow Transplant Clinical Trials Network Study. Presented at the European Group for Blood and Marrow Transplantation meeting, Paris, France, 2011. 32. Yanik G, White E, Mineishi S, Levine JE, Braun T, Cooke K. Tumour necrosis factor inhibition for the
treatment of sub-acute lung injury following allogeneic stem cell transplantation. . Presented at the European Group for Blood and Marrow Transplantation meeting, Paris, France, 2011. 33. Harris AC, Ferrara JLM, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E,
Landfried K, Akashi K, Vander Lugt MT, Reddy P, Chin A, Zhang Q, Hanash S, Paczesny S. A novel grading system of lower gastrointestinal acute graft-versus-host disease at disease onset predicts response to therapy and non-relapse mortality. Presented at the American Society of Hematology meeting, San Diego, California, 2011. 34. Vander Lugt MT, Braun T, Ferrara JLM, Hanash S, Levine JE, Wang CH, Zhang Q, Chin A, Harris AC, Choi
SW, Couriel D, Reddy P, Paczesny S. Plasma concentration of ST2, the IL33 receptor, at initiation of graft versus host disease therapy predicts day 28 response and day 180 survival post-treatment. Presented at the American Society of Hematology meeting, San Diego, California, 2011. 35. Vander Lugt MT, Braun T, Ferrara JLM, Hanash S, Levine JE, Wang CH, Zhang Q, Chin A, Harris AC, Choi
SW, Couriel D, Reddy P, Paczesny S. Plasma concentration of ST2, the IL33 receptor, at initiation of graft versus host disease therapy predicts day 28 response and day 180 survival post-treatment. Presented at the American Society of Blood and Marrow Transplantation meeting, San Diego, California, 2012. *winner, best basic science abstract 36. Pulsipher M, Chitphakdithai P, Logan B, Levine JE, Navarro W, Miller J, Confer D. Increased risk of severe
adverse events after BM versus PBSC donation: Results of a prospective study of 9494 NMDP donors, 2004-2009. Presented at the International Donor Registry Conference, Sydney, Australia, 2012.
Published abstracts
1. Levine JE, Higgins EM: A comparison of radiation treatment protocols for high-grade astrocytomas, 38
cases. American Medical Association Eastern Student Research Forum, 1987.
2. Sender LS, Brizuela MA, Cook C, Thomas J, Levine JE, Weinberg K: Targeted "knockout" of the interleukin-
2 (IL-2) gene in mouse embryonic stem cells. Society for Pediatric Research meeting, 1991.
3. Levine JE, Yang SY: Extensive polymorphism identified in HLA-C locus by sequence specific oligonucleotide
probe hybridization. American Society of Hematology meeting, 1993.
4. Levine JE, Wiley J, Kletzel M, Yanik GA, Hutchinson RJ, Neudorf S: The use of allogeneic peripheral blood
stem cell (PBSC) transplantation in pediatric patients. American Society of Hematology meeting, 1997.
5. Levine JE, Yanik GA, Hutchinson RJ, Sproles A, Casper J, Beatty PG, Collins R: Donor leukocyte infusions
(DLI) to treat relapses after allogeneic bone marrow transplantation in pediatric patients. American Society of Hematology meeting, 1997.
6. Yanik GA, Levine JE, Nandwani S, Hutchinson RJ: Graft versus host disease prophylaxis with tacrolimus
dosed to achieve low serum levels: Is it effective prophylaxis in pediatric patients receiving allogeneic marrow transplants? American Society of Hematology meeting, 1997.
7. Zeidler C, Levine JE, Bolyard A, Bonilla MA, Boxer L, Brown S, Dale DC, Cham B, Fier C, Freedman M,
Kannourakis G, Kinsey SE, Mori P, Welte K: Bone marrow transplantation (BMT) in patients with severe congenital neutropenia (SCN) refractory to G-CSF. American Society of Hematology meeting, 1998.
8. Zeidler C, Levine JE, Bolyard AA, Bonilla MA, Boxer L, Brown S, Dale DC, Cham B, Freedman M,
Kannourakis G, Kinsey SE, Mori P, Welte K. Outcomes for hematopoietic stem cell transplantation (HSCT) in severe congenital neutropenia (CN). American Society of Hematology meeting, 1999. 9. Gilman A, Bunin N, Levine JE, Joyce M, Anderson P, Bendel A, Pietryga D, Anderson R, Goldman F, Rozans
M, Sambrano J, Kadota R, Hetherington M. Dual cycle high-dose chemotherapy and stem cell rescue for recurrent brain tumors. American Society of Pediatric Hematology/Oncology meeting, 2000.
10. Uberti J, Ayash L, Reynolds C, Yanik GA, Levine JE, Hutchinson RJ, Ferrara JLM, Silver SM, Clarke M,
Ratanatharathorn V. Lower intensity of preparative regimen for allogeneic stem cell transplantation with advanced hematologic malignancy is associated with poor outcome. American Society of Hematology meeting, 2000.
11. Levine JE, Harris R, Loberiza F, Lazarus HM, van Besien KW, Vose JM, Horowitz MM. Allogeneic
transplants are associated with fewer relapses but higher treatment related mortality than autologous transplants for lymphoblastic lymphoma. American Society of Hematology meeting, 2001.
12. Uberti JP, Ayash L, Reynolds C, Silver SM, Hutchinson RJ, Ferrara JLM, Yanik GA, Levine JE,
Ratanatharathorn V. Chronic graft-vs-host disease after sibling allogeneic PBSC transplants may improve relapse and survival. American Society of Hematology meeting, 2001.
13. Zeidler C, Schwinzer B, Pracht G, Dale DC, Levine JE, Sykora KW, Welte K. Hematopoietic stem cell
transplantation in congenital neutropenias: Recommendation for patients refractory to G-CSF treatment and secondary MDS or leukemias. American Society of Hematology meeting, 2003.
14. Yanik GA, Uberti JP, Ferrara JLM, Levine JE, Hutchinson RJ, Ho VT, Cooke KR. Soluble tumor necrosis
factor receptor: Enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome following allogeneic stem cell transplantation. American Society of Blood and Marrow Transplantion meeting, 2004.
15. Alexander B, Wechsler D, Herman J, Braun T, Yanik GA, Hutchinson RJ, Levine JE, Pierce L. Role of cranial
boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia. American Society for Therapeutic Radiology and Oncology meeting, 2004.
16. Reynolds CM, Levine JE, Uberti JP, Ratanatharathorn V, Ayash LJ, Silver SM, Yanik GA, Reddy PR, Cooke
KR, Becker MW, Hutchinson RJ, Ferrara JLM. Keratinocyte growth factor (palifermin) in combination with tacrolimus and methotrexate for the prevention of acute graft-vs-host disease (aGVHD) in patients at high risk of aGVHD. American Society of Hematology meeting, 2004.
17. Choi S, Islam S, Yanik GA, Levine JE, Hutchinson RJ, Ferrara JLM, Greenson JK, Cooke KR. The use of
laparoscopic liver biopsies in pediatric patients with hepatic dysfunction following allogeneic hematopoietic stem cell transplantation. American Society of Hematology meeting, 2004.
18. Im EK, Cronin S, Levine JE, Braun T, Yanik GA, Reynolds C, Uberti JP, Ferrara JLM, Hutchinson RJ. The
impact of age and obesity on plasma busulfan levels. American Society of Blood and Marrow Transplantation meeting, 2005.
19. Thornburg CD, Levine JE, Pipe SW Adherence to prophylactic FVIII or FIX infusions in patients with
hemophilia Pediatric Academic Societies meeting, 2005.
20. Frangoul H, Woolfrey A, Khan S, Pulsipher M, Levine JE, Baker D, Walters M, Ayas M, Ravindranath Y,
Grupp S, Billheimer D, Nemecek E. A prospective study of G-CSF primed bone marrow from pediatric donors as a stem cell source for allogeneic bone marrow transplant: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. American Society of Hematology meeting, 2005.
21. Levine JE, Yanik GA, Cooke KR, Reddy P, Hutchinson RJ, Krijanovski O, McMahon C, Whitfield J, Ferrara
JLM. Elevated TNF receptor levels early after myeloablative BMT predict for GVHD and death. American Society of Blood and Marrow Transplantation meeting, 2006. 22. Sleight B, Ananthanarayanan G, Shenoy S, Haight A, Voram R, Prabhakar U, Schultz K, Gilman A, Gamis A, Levine JE, Braun T, Yanik GA. A pediatric pharmacokinetic study using anti-tumor necrosis factor antibody
(Infliximab) in patients with acute graft versus host disease involving the gastrointestinal tract. American
Society of Blood and Marrow Transplantation meeting, 2006.
23. Kato K, Khaled Y, Braun T, Levine JE, Ferrara JLM, Mineishi S, Yanik GA. Superior disease-free survival in
acute myelogenous leukemia/myelodysplastic syndrome receiving reduced-intensity allogeneic hematopoietic stem cell transplantation from unrelated donors using fludarabine, busulfan, and total lymphoid irradiation American Society of Blood and Marrow Transplantation meeting, 2007.
24. Kitko CL, Paczesny S, Richardson J, Choi S, Yanik G, Ferrara J, Levine JE. Chronic GVHD: Analysis of
incidence and potential for discovery of biomarkers. NIH Child Health Research Center meeting, 2007.
25. Khaled Y, Kato K, Levine JE, Mellacheruvu S, Jakubowiak A, Krijanovski O, Peres E, Reddy P, Knott K,
Yanik G, Ferrara J, Mineishi S. Superior long term progression free survival of myeloablative allogeneic hematopoietic stem cell transplantation for multiple myeloma compared to autologous hematopoietic stem cell transplantation after identical conditioning regimen. American Society of Hematology meeting, 2007.
26. Peres E, Levine J, Kato K, Krijanovski O, Khaled Y, Ferrara J, Yanik G, Mineishi S. Reduced intensity versus
full myeloablative stem cell transplant for advanced chronic lymphocytic leukemia. American Society of Blood and Marrow Transplantation meeting, 2008.
27. Kato K, Krijanovski O, Khaled Y, Peres E, Reddy P, Choi S, Kitko C, Yanik G, Levine J, Ferrara J, Mineishi S.
Allogeneic hematopoietic stem cell transplantation has curative potential for chemorefractory non-Hodgkin lymphoma. American Society of Blood and Marrow Transplantation meeting, 2008.
28. Khaled YA, Abidi MH, Janakiraman N, Kato K, Hanbali A, Levine JE, Ferrara JL, Mineishi S. History of prior
radiation therapy predicts poor progression free survival and overall survival in African Americans with multiple myeloma after autologous stem cell transplantation. American Society of Blood and Marrow Transplantation meeting, 2008. 29. Mineishi S, Magenau J, Pawarode A, Buck T, Jones D, Kato K, Frame D, Kujawski L, Erba H, Khaled Y, Peres E, Krijanovski O, Reddy P, Kitko C, Choi S, Yanik G, Ferrara JLM, Braun T, Levine JE. Myeloablative
conditioning with Clofarabine and Busulfan x 4 (CloBu4) is well tolerated, facilitates secure engraftment, and
exhibits significant anti-tumor activity against non-remission hematological malignancies including AML.
American Society of Hematology meeting, 2008.

30. Sisler I, Domm J, Ryan R, Levine J, Pulsipher M, Haut P, Schultz KR, Koyama T, Koehler E, Taylor D,
Frangoul H. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplant for children with AML beyond the first complete remission: total body irradiation versus busulfan- a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. American Society of Hematology meeting, 2008.
31. Maslak J, Kaul D, Connelly J, Mineishi S, Levine JE, Peres E, Kitko C, Choi S, Khaled Y, Krijanovski O,
DiGiandomenico S, White E, Braun T, Reddy P, Pawarode A, Ferrara JLM, Yanik GA Bronchoscopic evaluation of pulmonary complications in patients undergoing reduced-intensity versus full- intensity transplants. American Society of Hematology meeting, 2008. 32. Kitko C, Mineishi S, Braun T, Choi S, Jones D, Harris A, Khaled Y, Krijanovski O, Paczesny S, Peres E, Yanik G, Whitfield J, Ferrara J, Levine JE. Day7 TNFR1 levels following reduced intensity allogeneic
hematopoietic stem cell transplant (HCT) predict for acute GVHD. American Society of Blood and Marrow
Transplantation meeting, 2009.


33. Magenau J. Maslak J, Mineishi S, Digiandamenico S, Braun T, Levine JE, Yanik GA. Impaired pre-transplant
FEV1 is associated with reduced overall and disease free survival following allogeneic transplant for acute myelogenous leukemia. American Society of Blood and Marrow Transplantation meeting, 2009. 34. Magenau J, Pawarode A, Buck T, Jones D, Kato K, Frame D, Kujawski L, Erba HP, Khaled Y, Peres EM, Krijanovski OI, Reddy P, Kitko C, Choi S, Yanik G, Braun T, Ferrara JLM, Levine JE, Mineishi S. Conditioning
with clofarabine and busulfan X 4 (CloBu4) for non-remission hematologic malignancies including AML is well
tolerated, facilitates secure engraftment, and exhibits significant anti-tumor activity. American Society of Blood
and Marrow Transplantation meeting, 2009.


35. Ramakrishnan A, Buck T, Levine J, James P. Allowing greater use of institutional practice may decrease cost
of CTN trials. American Society of Blood and Marrow Transplantation meeting, 2009.
36. Buck TA, James P, Levine JE, Ramakrishnan A. Streamlining SAE reporting for CTN trials results in
significant time savings. American Society of Blood and Marrow Transplantation meeting, 2009.
37. Anuszkiewicz SK, Levine JE, Jones DM. Building a foundation to excel at conducting clinical and translational
research. American Society of Blood and Marrow Transplantation meeting, 2009.
38. Little AM, Frame D, Levine JE, Ferrara JL, Arnoldi S, Kleibocker S, Malani PN, Ramm C, Kaul DR. The utility
of urinary BK viral loads in predicting late-onset hemorrhagic cystitis in allogeneic stem cell transplant recipients. Infectious Disease Society of America meeting, 2009. 39. Pulsipher MA, Chitphakdithai P, Logan BR, Goldstein SC, Levine JE, Lankiewicz M, Stroncek D, Confer DL,
Peripheral blood stem cell (PBSC) donors experience higher levels of pain and toxicities early on, while bone marrow (BM) donors experience slower recovery and more late pain: A prospective study of the national marrow donor program (NMDP). American Society of Hematology meeting, 2010. 40. Cooling L, Bombery M, Hoffmann S, Robertson P, Levine JE, Davenport RD. Vincristine can adversely
impact autologous peripheral blood stem cell collection in children. AABB annual meeting, 2011. 41. Hoodin F, Zhao L, Carey J, Gourley B, Richard A, Proudfoot S, Levine JE, Riba M, Kitko C. Hematopoeitic
cell transplant (HCT) survivorship: Does psychological screening make a difference in management of psychological problems? Society of Behavioral Medicine meeting, 2012. 42. Kitko C, Zhao L, Carey J, Gourley B, Richard A, Proudfoot S, Mineishi S, Couriel D, Levine JE, Riba M,
Hoodin F. Hematopoeitic cell transplant (HCT) survivorship: How much variance in depressive symptoms can be accounted for by biomedical variables? American Society of Blood and Marrow Transplantation meeting, 2012. 43. Kamani NR, Walters M, Carter S, Brochstein JA, Eapen M, Levine JE, Logan B, Panepinto J, Parikh S,
Pulsipher M, Schultz KR, Shenoy S. Unrelated donor cord blood transplantation for children with severe sickle cell disease: Results of a phase II study from the Blood and Marrow Transplant Clinical Trials Network. American Society of Blood and Marrow Transplantation meeting, 2012.

Source: http://www.haematologie-onkologie-2012.de/media/Fotos/Gastredner/Levine_CV_4-12.pdf

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia

International Journal of Neuropsychopharmacology (2005), 8, 457–472. Copyright f 2005 CINPdoi :10.1017/S146114570500516XA meta-analysis of neuropsychological changeto clozapine, olanzapine, quetiapine, andNeil D. Woodward1, Scot E. Purdon2, Herbert Y. Meltzer3 and David H. Zald11 Department of Psychology, Vanderbilt University, Nashville, TN, USA2 Department of Psychiatry, University of Al

Mediapart "48h"

Directeur de la publication : Edwy Plenel«Après le Mediator, le scandale à venir est celui des traite-ments anti-Alzheimer !»Par Sylvain BourmeauArticle publié le mardi 04 janvier 2011Lacouverture de l’affaire du Mediator, ce médicament des labo-C’est un médecin qui écrit après le passage dans son cabinet d’unratoires Servier rendu responsable de la mort de 500 à 2.000 p

Copyright © 2010-2014 Drugstore Pdf Search